

**COMPANY
DIRECTORY**
참가업체 안내

BIO KOREA 2025

2025.05.07 ~ 05.09

코엑스 Hall C
캐나다 국가관 (부스번호 C1)

Canada



ONTARIO
CANADA



Government
of Canada

Gouvernement
du Canada



BIO KOREA 2025

- 주한캐나다대사관 소개 · 3
- B.C.주 한국대표부 소개 · 4
- Ontario 주 무역투자 한국사무소 소개 · 5

캐나다 참여기업

AI

- Acceleration Consortium · 6
- Variational AI · 7

Biotech

- QurCan Therapeutics Inc. · 8
- Spiderwort Biotechnologies Inc · 9

Contract Research Organizations (CROs) & Research Center

- Atuka Inc. · 10
- CIDGOH (Centre for Infectious Disease Genomics and One Health) · 11

NonProfit Organization

- CCRM (Centre for Commercialization of Regenerative Medicine) · 12
- VIDO (Vaccine and Infectious Disease Organization) · 13

Pharmaceutical

- Juno Pharmaceuticals · 14

주한캐나다대사관

상무과 소개

주한캐나다대사관 상무과 (The Canadian Trade Commissioner Service) 는 캐나다 제약 및 바이오 산업을 알리기 위해 BIO KOREA 2025 캐나다관을 운영합니다.

주한캐나다대사관 상무과는 캐나다 연방정부 외교통상부소속으로 한국에 진출하고자 하는 캐나다 기업이 보다 빠르고 나은 결정을 내릴 수 있도록 캐나다 기업에게 한국 시장 및 기업 정보, 그리고 협력 기회 및 시장 진출 관련 조언 등을 제공 합니다.

또한 한국 기업들에게는 캐나다 기업과의 협력 기회 및 관련 행사 등을 안내 드리고, 캐나다 투자 진출 지원 업무를 제공하여 캐나다 진출을 희망하는 한국 기업에게 캐나다 투자 환경 및 다양한 인센티브등을 안내해드립니다.

캐나다 기업 및 기관과의 협력을 희망하시거나, 관련 문의 사항이 있으신 분은 하기 담당자에게 문의 하시기 바랍니다.

담당 상무관

김지민 주한캐나다대사관 Life Sciences 담당 상무관
Tel. 02-3783-6114
jimin.kim@international.gc.ca



B.C. 주 한국대표부

한국-캐나다 자유 무역 협정(CKFTA)을 통해 브리티시 컬럼비아(B.C.)와 한국은 긴밀한 관계와 광범위한 비즈니스 협력을 구축하고 있습니다. 특히 석탄, 구리, 가공되지 않은 알루미늄, 목재 펄프를 비롯한 다양한 원자재가 캐나다에서 수출되며, 기술 중심 산업 분야에서 선도적인 역할 하는 한국이 이를 가공함에 있어 B.C. 주와의 협력을 통해 추가적인 핵심 산업 분야에서 다양한 협력과 무역, 투자 기회가 있습니다.

B.C. 주 한국대표부는 한국과 B.C.주 기업들이 식품, 소비재, 운송, 디지털 엔터테인먼트, 정보 통신 기술, 청정 기술, 재생 가능 에너지, 해양 기술, 생명 과학, 그리고 교육 분야를 포함한 다양한 분야에서 기회를 모색할 수 있도록 적극적으로 지원하고 있습니다. B.C. 주 한국대표부는 한국 기업과 캐나다 B.C.주에서의 파트너십 및 수출 기회를 연결하고 기업의 한국 시장 진출을 지원하는 역할을 합니다. 한국과 B.C. 주를 연결하는 교두보 역할을 하는 저희 사무실은 15개 이상의 다양한 산업 분야에 있어 서비스를 제공하고 있습니다.

관련 문의사항이 있으시면 아래의 연락처로 문의해주시기 바랍니다.

SEOUL-BC-CB@international.gc.ca

온타리오주 무역투자대표부

주한캐나다대사관 내에 위치하고 있는 온타리오주 무역투자대표부(TIO, Trade and Investment Office)는 온타리오주와 대한민국 간 무역 및 투자를 촉진하는 교두보 역할을 하고 있습니다.

온타리오주 무역투자대표부는 국제무대에서의 온타리오주 이미지를 제고하고 주요 글로벌 시장에서 공고한 상업적 파트너십을 구축하기 위해 노력하고 있습니다. 또한, 캐나다 연방정부, 주정부, 지자체와의 협력을 통해 온타리오주의 경제적 기반을 굳건히하고, 온타리오주와 대한민국의 성장과 혁신을 위한 상호이익의 기회를 만들어가기 위해 노력하고 있습니다.

온타리오주 무역투자대표부의 역할

온타리오 진출을 희망하는 한국기업 지원 :

- 온타리오주에서 사업을 확장할수 있도록 사업비용 및 인센티브 등의 데이터와 정보 제공
- 성공적인 사업확장을 위한 정부, 기관, 민간파트너와의 연결 지원
- 사업확장에 필요한 현지 방문 및 분야별 현장 전문가 지원

온타리오 제품, 기술 및 서비스 홍보 :

- 국제 사절단 및 무역박람회에 참여하여 바이어와 온타리오 기업 간 네트워킹 기회 제공
- 온타리오 기업과의 직접연결을 통해 제품과 서비스를 홍보할 수 있도록 미팅 추진
- 인바운드/ 아웃바운드 무역사절단과 무역박람회에 참석할 수 있도록 파트너와 협력

온타리오주와 한국간 상업적 R&D 파트너십 촉진 :

- 온타리오주와 한국기업간의 상업적 R&D 파트너십을 촉진하기 위해 협력 추진

관련 문의사항이 있으시면 아래의 연락처로 문의해주시기 바랍니다.

연계환 수석상무관

Telephone: +82-2-3783-6024

Email: Kye.An@international.gc.ca

Website: <https://www.sourcefromontario.com/ko/page/tio-seoul#what-we-do>

Acceleration Consortium

Organization Type Academic Research Center

Expertise AI & robotics for accelerated materials discovery

Company Profile Based at the University of Toronto, we are a global network of government, academia, and industry working to accelerate the discovery of materials using AI and robotics.

Meeting Objective To meet with partners interested in the accelerated discovery of materials (such as small molecule drugs, semiconductors, polymers, and more) using AI and automation.

Website <https://acceleration.utoronto.ca>

Variational AI

Organization Type AI Drug Discovery

Expertise Generative AI for small molecule drug design

Company Profile

Variational AI is a techbio company with proprietary platform technology for de novo small molecule drug design. The company launched first commercially accessible foundational model for drug discovery with generative AI based drug design and retrosynthesis capability.

Enki is a pre-trained foundation model for small molecule drug discovery. Enki's proprietary algorithm trained on 450M+ experimental and computational samples for 700+ drug targets.

Enki is a fully trained generative AI foundation model that rapidly generates novel and diverse leads and performs lead optimisation. Enki is capable of designing lead-like molecules in line with the collaborators TPP. Every designed molecule by Enki incorporates synthetic accessibility information so that the proposed molecules can be made and tested in the lab.

Meeting Objective

We are looking to meet potential bio-pharma partners to explore potential collaboration opportunities.

Website

<https://variational.ai>

QurCan Therapeutics Inc.

Organization Type Biotech

Expertise RNA/DNA delivery using novel nanoparticle platform

Company Profile QurCan Therapeutics has developed a novel nanoparticle drug delivery technology (TERP) to enable systemic delivery of RNA therapeutics (ASOs, siRNA, mRNA) to extrahepatic tissues, including CNS and Spleen. We have world-leading expertise in the design of polymer shell nanoparticles and TERP is an IND-ready breakthrough technology with the great potential to deliver a new era of disease-modifying genetic medicine.

We are working with several biopharma companies to help develop TERP-enabled therapeutics for multiple applications while building an internal pipeline of therapeutics focused on monogenic CNS disorders.

Meeting Objective We would like to meet with investors and clinical-stage companies that are interested in exploring our technology to deliver genetic medicine safely and effectively to treat chronic and genetic diseases.

Website <https://www.QurCan.com>

Spiderwort Biotechnologies Inc.

Organization Type Biotech

Expertise Plant-based biomaterials for regenerative medicine applications

Company Profile

Spiderwort Biotechnologies is a clinical stage company developing plant-derived cellulose biomaterials for use in several regenerative medicine applications. The company's proprietary AeroCell™ biomaterial platform involves isolating and manufacturing a repertoire of unique cellulose derived microstructures to match the extracellular matrix structure of the target tissues.

Our biomaterial platform provides multiple advantages compared to its competitors.

First, the platform offers precise control over stiffness, shape, texture, and architecture of the biomaterial to be able to control tissue regeneration. Second, the biomaterials are biocompatible and immunologically inert in *in vitro* and *in vivo* models (FDA ISO 10993). Third, the biomaterials support cell infiltration and vascularization. Fourth, the platform allows the functionalization of biomaterials (e.g., material coating, drug delivery, cell adhesion). Finally, the biomaterials are GMP manufactured in a certified ISO 5 cleanroom (ISO 13485, ISO 14971).

Spiderwort Biotechnologies is developing two lead proprietary products using its AeroCell™ biomaterial platform. CelluBridge® is a spinal cord injury scaffold that has been granted a Breakthrough Device Designation from the US Food and Drug Administration (FDA), and CelluJuve® a dermal filler for soft tissue augmentation for aesthetic enhancement.

Meeting Objective

We would like to meet with Korean aesthetic companies to discuss possible collaboration on CelluJuve®.

Also, we would like to connect with Korean companies interested in exploring strategic partnerships for our spinal cord injury scaffold CelluBridge® and its AeroCell™ biomaterial platform.

Website

<https://spiderwortbio.com>

Atuka Inc.

Organization Type CRO

Expertise Preclinical research in neurodegeneration & gene therapy

Company Profile

Preclinical CRO: Historically focused on Parkinson's disease, we have now expanded our services to include cognition assessments, biodistribution studies (e.g., AAVs for gene therapy), and non-GLP safety evaluations.

Specialists: We are experts in non-human primate models of neurodegenerative diseases, providing our partners with the most relevant and translatable data for their therapeutic development programs.

Key advantages: Atuka empowers our partners to make critical, informed decisions at the crucial juncture between preclinical and clinical phases of drug development. We leverage our unparalleled expertise in neuroscience and Parkinson's disease, along with a leading array of rodent and non-human primate models and gene therapy experience, to craft the most tailored programs for any potential therapeutic.

Study design: Unlike organizations that offer standardized approaches, we design each preclinical study based on the unique mode of action and potential indication of our partner's therapeutic. This ensures the highest degree of translatability to Phase II clinical proof-of-concept, whether for overall efficacy or target engagement.

Quality: Atuka delivers the highest-quality studies and data, interpreted by world-leading neuroscientists, to provide results that are consistently predictive and translatable.

Meeting Objective

We would like to meet with Korean companies in the disease areas that Atuka covers. We believe we are the premium CRO worldwide in the Parkinson's disease and have many decades of experience within the management team at helping companies evaluate their potential therapies. We would also like to highlight our services in gene therapy, such as biodistribution of AAVs. Our unique access to non-human primates means we can run large studies that can also combine our expertise in stereotactic surgery for direct injections into brain areas if needed.

Website <https://atuka.com>

CIDGOH

(Centre for Infectious Disease Genomics and One Health)

Organization Type

Academic Research Center / CRO

Expertise

Genomics-driven infectious disease research & data infrastructure

Company Profile

CIDGOH, at Simon Fraser University, combines knowledge engineering techniques (e.g. ontology modeling, data curation, semantic web), bioinformatics tools (e.g. genomic sequence analysis, phylogenetic, comparative genomics, text mining, workflow and platform development) and molecular laboratory experiments (microbial genomics, metagenomics, eDNA, and virome) to understand the impact of infectious diseases on human and animal health.

Developing technologies to foster data harmonization and sharing, and building trusted networks of health care practitioners, researchers, and policy makers are therefore key focuses of the Centre.

Meeting Objective

We are interested in working with partners to generate data, to analyze data, and to share (and re-use) data for the broader benefit of the scientific community. Our facility includes a state-of-the-art molecular laboratory for microbial sample processing and omics data generation and access to high-performance computing clusters and cloud computing (courtesy of Compute Canada) to provide a “one-stop-shop” for research and collaboration.

Website

<https://cidgoh.ca>

CCRM

(Centre for Commercialization of Regenerative Medicine)

Organization Type Non-Profit Organization

Expertise Commercialization & manufacturing of regenerative medicine

Company Profile

CCRM, a Canadian public-private partnership established with seed funding by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.

A network of academic researchers, leading companies, strategic investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding and infrastructure.

CCRM sources and evaluates IP from around the globe, conducts development projects with partners, and establishes new companies built around strategic bundles of IP.

CCRM has a 40,000 ft² space dedicated to advanced cell manufacturing that includes a fully resourced process development facility and a GMP facility.

In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-scale CDMO for manufacturing gene-modified cells and viral vectors. CCRM is hosted by the University of Toronto and launched in 2011.

Website <https://www.ccrm.ca>

VIDO

(Vaccine and Infectious Disease Organization)

Organization Type Non-Profit Organization

Expertise Infectious disease R&D, vaccine development, high-containment labs

Company Profile

The Vaccine and Infectious Disease Organization (VIDO) is a world leader in infectious disease research and vaccine development for humans and animals. VIDO's expertise, infrastructure, and history put us at the forefront of innovation and make us a valuable resource and a source of pride for Canada. For 5 decades, we have been developing solutions to emerging threats and currently have over forty animal models of infectious disease.

VIDO is expanding our capabilities as a Centre for Pandemic Research. This includes our Vaccine Development Centre, a containment level 3 capable biomanufacturing facility that meets GMP requirements, adding containment level 4 capacity and building a new animal facility capable of housing a wider range of animals to expand our preclinical research and development capacity. These important enhancements will support scientists from Canada and around the world to develop vaccines and therapeutics for humans and animals.

Our containment infrastructure and infectious disease expertise is accessible to Government, Industry and Academia on a contract basis.

Meeting Objective

Our primary objective is to expand our partnerships in the region with a priority on pharmaceutical/biotech companies and research institutes. Pandemic preparedness requires a network of high containment labs and a range of medicines from vaccines to antivirals/antibiotics as well as therapeutics. Vaccine antigen design using computational AI is a growing area of significance for VIDO. Since most new infectious diseases have links to animals VIDO is looking for strategic partnerships that synergize with our 'one-health' expertise that align with our mission and vision and have technologies or expertise that create natural synergies.

Website <https://www.vido.org>

Juno Pharmaceuticals

Organization Type Pharmaceutical

Expertise Generics, complex generics, specialty pharmaceuticals, medical devices

Company Profile

Juno Pharmaceuticals is a Canadian based consortium of international specialty pharmaceutical and healthcare companies led by a team of highly skilled experts, with decades of collective industry experience.

Our business model is to invest in and help support the development of front-end businesses around the world, but with a primary focus in the territories of Australia, Canada, South Africa, and the UK. Corporate resources, such as finance, intellectual property, and business development experts are shared amongst the Juno global network generating topline sales more than \$600M in 2024.

Throughout our network, Juno operates across a range of spaces within the pharmaceutical market, from branded to generic, and hospital to retail.

Our focus and expertise have been directed towards the identification and in-licensing of scarce and niche generic pharmaceuticals with inherent barriers to market entry. The targeting of these opportunities means we have a robust commercial focus in our markets, with experienced commercial and regulatory departments with a proven track record of detailing products to specialists and achieving approvals for complex pharmaceutical products.

Juno is one of the largest specialty injectable businesses in Canada. Our Montreal based parenteral manufacturing facility is EU GMP and FDA certified and currently exports to over 20 markets worldwide.

Meeting Objective

To meet with potential Korean partners for collaboration and co-development of value-added generics and products of scarcity, and to introduce our Montreal sterile injectable manufacturing facility

Website

<https://www.junopharm.ca>

Canada

주한캐나다대사관 김지민 상무관

jimin.kim@international.gc.ca

02 3783 6114

서울특별시 중구 정동길 21 www.korea.gc.ca